Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Vincelli ID, Martino EA, Vigna E, Bruzzese A, Mendicino F, Botta C, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Falcone AP, Cangialosi C, Reddiconto G, Farina G, Barone M, Rizzello I, Iaccino E, Mimmi S, Curci P, Gamberi B, Musto P, De Stefano V, Musso M, Petrucci MT, Offidani M, Di Raimondo F, Boccadoro M, Cavo M, Neri A, Gentile M. Morabito F, et al. Among authors: mendicino f. Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376. eCollection 2022. Front Oncol. 2022. PMID: 35924160 Free PMC article.
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
Ciliberto D, Staropoli N, Caglioti F, Gualtieri S, Fiorillo L, Chiellino S, De Angelis AM, Mendicino F, Botta C, Caraglia M, Tassone P, Tagliaferri P. Ciliberto D, et al. Among authors: mendicino f. Cancer Biol Ther. 2015;16(8):1148-59. doi: 10.1080/15384047.2015.1056415. Epub 2015 Jun 10. Cancer Biol Ther. 2015. PMID: 26061272 Free PMC article.
Bendamustine in multiple myeloma.
Gentile M, Vigna E, Recchia AG, Morabito L, Mendicino F, Giagnuolo G, Morabito F. Gentile M, et al. Among authors: mendicino f. Eur J Haematol. 2015 Nov;95(5):377-88. doi: 10.1111/ejh.12609. Epub 2015 Jul 14. Eur J Haematol. 2015. PMID: 26085055 Review.
Pomalidomide in multiple myeloma.
Uccello G, Petrungaro A, Mazzone C, Recchia AG, Greco R, Mendicino F, Lucia E, Vigna E, Morabito F, Gentile M. Uccello G, et al. Among authors: mendicino f. Expert Opin Pharmacother. 2017 Feb;18(2):133-137. doi: 10.1080/14656566.2016.1274973. Epub 2016 Dec 26. Expert Opin Pharmacother. 2017. PMID: 28002973 No abstract available.
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies.
Vigna E, Petrungaro A, Perri A, Terzi D, Recchia AG, Mendicino F, La Russa A, Bossio S, De Stefano L, Zinno F, Bonofiglio R, Morabito F, Gentile M. Vigna E, et al. Among authors: mendicino f. Transfus Apher Sci. 2018 Apr;57(2):247-249. doi: 10.1016/j.transci.2018.03.005. Epub 2018 Mar 15. Transfus Apher Sci. 2018. PMID: 29567368
Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications.
Malato A, Rossi E, Tiribelli M, Mendicino F, Pugliese N. Malato A, et al. Among authors: mendicino f. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):588-595. doi: 10.1016/j.clml.2020.04.015. Epub 2020 Apr 30. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32482540 Free article. Review.
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report.
Botta C, Caruso N, Bossio S, Storino F, Console G, Martino M, Mendicino F, Lucia E, Morelli R, Correale P, Morabito F, Gentile M, Vigna E. Botta C, et al. Among authors: mendicino f. Front Oncol. 2020 Jun 18;10:967. doi: 10.3389/fonc.2020.00967. eCollection 2020. Front Oncol. 2020. PMID: 32626658 Free PMC article.
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
Gentile M, Martino EA, Visentin A, Coscia M, Reda G, Sportoletti P, Mauro FR, Laurenti L, Varettoni M, Murru R, Chiarenza A, Vigna E, Mendicino F, Lucia E, Bossio S, Recchia AG, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vitale C, Tripepi G, D'Arrigo G, Angeletti I, Bomben R, Neri A, Cutrona G, Fronza G, Di Raimondo F, Gaidano G, Cuneo A, Foà R, Ferrarini M, Trentin L, Gattei V, Morabito F. Gentile M, et al. Among authors: mendicino f. Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3. Blood Cancer J. 2020. PMID: 32938904 Free PMC article. No abstract available.
51 results